Jesper Brandgaard/LinkedIn
Dec 7, 2025, 05:45
Jesper Brandgaard: Novo Nordisk Haemophilia Foundation is Evolving into the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation
Jesper Brandgaard, Chairman at LEO Pharma, posted on LinkedIn:
“As the former President of the Council, I am absolutely delighted to share that the Novo Nordisk Haemophilia Foundation is evolving into the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation. It’s truly inspiring to witness the mission grow to support even more lives. A huge thank you to the Novo Nordisk Foundation for joining as an accelerating partner on this ambitious journey to quadruple the annual beneficiaries by 2030.
Congratulations to the entire NNHF Council and Team – here’s to an exciting new era ahead!”
Get the latest with Hemostasis Today.
-
Jan 22, 2026, 15:36We Must Roll Up Our Sleeves And Help: José Antonio García Erce on Plasma Donation
-
Jan 22, 2026, 15:25Nita Radhakrishnan on Challenges In Congenital Afibrinogenemia
-
Jan 22, 2026, 15:10Jin Q Gives a Summary of 2025’s Most Impactful Cell and Gene Therapy Milestones
-
Jan 22, 2026, 14:57Nirav Dhanesha on CD14 Acting As A Functional Driver of DVT
-
Jan 22, 2026, 11:41Jamilla Goedegebuur and Colleagues on VTE Management in Case of PAD
-
Jan 22, 2026, 11:28Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
-
Jan 22, 2026, 11:19Bruno Odisio: Ablation Margins Are Software-Dependent
-
Jan 22, 2026, 10:38Pedro Perez: The VTE Market Is Clearly Entering Its Next Phase
-
Jan 22, 2026, 10:29Marvin Garcia Reyes Presents a Case of Aorto-Visceral and Aorto-Iliac Thrombosis